Tag:
Halaven
Latest Headlines
Latest Headlines
Eisai discount doesn't sway NICE on Halaven
NICE said Eisai's breast cancer treatment still didn't meet the requirements for cost-effectiveness, partly because of troublesome side effects.
NICE stuns Eisai with Halaven rejection
The U.K.'s National Institute for Health and Clinical Excellence has issued draft guidance stating it is unable to recommend Eisai's Halaven to treat metastatic breast cancer in patients whose
Eisai looks for $1B from new breast cancer drug
Winning the U.S. nod for breast cancer treatment Halaven is just Eisai's first step toward building up the drug. Now FDA-approved for late-stage breast cancer in women who've failed on at least two
Eisai gains cancer drug approval as it takes a big patent hit
Japan's Eisai has picked up a key regulatory win at the FDA, gaining approval to start selling a new breast cancer drug as a third-line therapy just as its big Alzheimer's drug--Aricept--rolls off
